OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CENG55

Cengild Medical Bhd

Healthcare Facilities & ServicesVerified

Cengild Medical Bhd maintains a strong liquidity position, with a current ratio of 8.08, indicating a substantial buffer of current assets over current liabilities. However, the company reported negative operating cash flow of MYR -1.672 million, which may signal short-term cash flow challenges despite the high current ratio. Free cash flow is minimal at MYR 34,000, suggesting limited capacity for reinvestment or shareholder returns. The debt-to-equity ratio of 0.13 reflects a conservative capital structure, with long-term debt at MYR 13.941 million compared to total equity of MYR 109.718 million. Profitability metrics show a return on equity (ROE) of 2.77% and a return on assets (ROA) of 2.23%, both below the industry median for healthcare facilities and services. The net income of MYR 3.041 million on revenue of MYR 17.051 million yields a net margin of 17.83%, which is relatively strong but must be compared to industry benchmarks to assess competitive positioning. The company's revenue is not segmented by product or geography in the available data, but the high concentration of revenue in a single business model (medical services and pharmaceuticals) suggests potential exposure to sector-specific risks. The lack of geographic diversification may limit resilience in the face of regional economic or regulatory shifts. Looking ahead, the company's revenue outlook is constrained by the current operating cash flow challenges and limited free cash flow. While the capital expenditure of MYR -2.111 million indicates ongoing investment, the scale of these expenditures relative to revenue and cash reserves is modest. The company's growth trajectory will depend on its ability to convert operating income into sustainable cash flow. The risk assessment highlights a medium liquidity risk due to the negative operating cash flow and low free cash flow, despite the high current ratio. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of recent material events or disclosures suggests a stable but potentially stagnant business environment for Cengild Medical Bhd.

30-day price · CENG+0.00 (+0.0%)
Low$0.20High$0.21Close$0.21As of12 May, 00:00 UTC
Profile
CompanyCengild Medical Bhd
TickerCENG.KL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Cengild Medical Bhd operates in the healthcare sector, providing medical services and pharmaceutical products, primarily generating revenue through service delivery and product sales.

Classification. Cengild Medical Bhd is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Cengild Medical Bhd maintains a strong liquidity position, with a current ratio of 8.08, indicating a substantial buffer of current assets over current liabilities. However, the company reported negative operating cash flow of MYR -1.672 million, which may signal short-term cash flow challenges despite the high current ratio. Free cash flow is minimal at MYR 34,000, suggesting limited capacity for reinvestment or shareholder returns. The debt-to-equity ratio of 0.13 reflects a conservative capital structure, with long-term debt at MYR 13.941 million compared to total equity of MYR 109.718 million. Profitability metrics show a return on equity (ROE) of 2.77% and a return on assets (ROA) of 2.23%, both below the industry median for healthcare facilities and services. The net income of MYR 3.041 million on revenue of MYR 17.051 million yields a net margin of 17.83%, which is relatively strong but must be compared to industry benchmarks to assess competitive positioning. The company's revenue is not segmented by product or geography in the available data, but the high concentration of revenue in a single business model (medical services and pharmaceuticals) suggests potential exposure to sector-specific risks. The lack of geographic diversification may limit resilience in the face of regional economic or regulatory shifts. Looking ahead, the company's revenue outlook is constrained by the current operating cash flow challenges and limited free cash flow. While the capital expenditure of MYR -2.111 million indicates ongoing investment, the scale of these expenditures relative to revenue and cash reserves is modest. The company's growth trajectory will depend on its ability to convert operating income into sustainable cash flow. The risk assessment highlights a medium liquidity risk due to the negative operating cash flow and low free cash flow, despite the high current ratio. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of recent material events or disclosures suggests a stable but potentially stagnant business environment for Cengild Medical Bhd.
Key takeaways
  • Cengild Medical Bhd has a strong current ratio but faces short-term liquidity challenges due to negative operating cash flow.
  • The company's ROE and ROA are below industry medians, indicating room for improvement in asset and equity utilization.
  • Revenue concentration in a single business model and lack of geographic diversification increase sector-specific risk exposure.
  • Growth is constrained by limited free cash flow and modest capital expenditures relative to revenue.
  • The company's dilution risk is low, but its liquidity risk is medium due to negative net cash after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$17.1M
Gross profit$8.1M
Operating income$4.9M
Net income$3.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.7M
CapEx-$2.1M
Free cash flow$34.0k
Total assets$136.5M
Total liabilities$26.8M
Total equity$109.7M
Cash & equivalents
Long-term debt$13.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$63.5M$14.7M$10.0M$13.2M
FY-3$64.4M$13.0M$9.4M$13.4M
FY-2$70.3M$18.1M$13.3M$8.3M
FY-1$66.8M$17.7M$11.1M-$5.9M
FY0$80.0M$17.9M$11.1M-$25.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$46.0M$13.8M
FY-3$119.5M$93.0M
FY-2$131.7M$106.1M
FY-1$132.4M$111.3M
FY0$180.5M$114.5M
PeriodOCFCapExFCFSBC
FY-4$14.3M-$1.7M$13.2M
FY-3$14.1M-$427.7k$13.4M
FY-2$13.9M-$2.1M$8.3M
FY-1$12.9M-$15.7M-$5.9M
FY0$16.1M-$37.3M-$25.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$17.1M$4.9M$3.0M$34.0k
FQ-6$16.1M$3.7M$1.5M-$9.6M
FQ-5$22.2M$6.2M$4.0M$696.0k
FQ-4$20.0M$4.5M$2.9M$5.4M
FQ-3$18.5M$3.3M$1.9M-$2.1M
FQ-2$19.0M$4.9M$2.2M-$28.2M
FQ-1$18.7M$3.5M$2.9M-$19.5M
FQ0$18.5M$3.3M$2.7M-$36.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$136.5M$109.7M
FQ-6$132.4M$111.3M
FQ-5$136.3M$112.3M
FQ-4$174.3M$115.3M
FQ-3$169.9M$112.2M
FQ-2$180.5M$114.5M
FQ-1$197.6M$114.3M
FQ0$218.1M$117.0M
PeriodOCFCapExFCFSBC
FQ-7-$1.7M-$2.1M$34.0k
FQ-6$12.9M-$15.7M-$9.6M
FQ-5$5.5M-$2.3M$696.0k
FQ-4$17.7M-$2.0M$5.4M
FQ-3$15.4M-$2.7M-$2.1M
FQ-2$16.1M-$37.3M-$28.2M
FQ-1$7.6M-$23.8M-$19.5M
FQ0$8.5M-$60.8M-$36.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$109.7M
Net cash-$13.9M
Current ratio8.1
Debt/Equity0.1
ROA2.2%
ROE2.8%
Cash conversion-55.0%
CapEx/Revenue-12.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricCENGActivity
Op margin28.6%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin17.8%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin47.7%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-12.4%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity13.0%25.0% medp25 3.8% · p75 63.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 00:37 UTC#ac3d6f7c
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 15:11 UTCJob: 64385ece